

Amador Goodridge

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9053018/amador-goodridge-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

20,967
citations

24
h-index

63
g-index

63
ext. papers

26,295
ext. citations

16.7
avg, IF

4.05
L-index

#	Paper	IF	Citations
51	Phenotypic and genotypic characteristics of carbapenemase- and extended spectrum β -lactamase-producing clinical isolates within a hospital in Panama City. <i>Therapeutic Advances in Infectious Disease</i> , 2021 , 8, 20499361211054918	2.8	0
50	Probable long-term prevalence for a predominant Mycobacterium tuberculosis clone of a Beijing genotype in Colon, Panama. <i>Transboundary and Emerging Diseases</i> , 2021 , 68, 2229-2238	4.2	0
49	Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama. <i>Frontiers in Medicine</i> , 2021 , 8, 616108	4.0	4
48	Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama. <i>PLoS ONE</i> , 2021 , 16, e0257351	3.7	0
47	Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019. <i>Lancet Infectious Diseases, The</i> , 2021 ,	25.5	6
46	Re: "Genotyping and Molecular Characterization of Fluoroquinolone Resistance Among Multidrug-Resistant in Southwest of China" by Hu et al.. <i>Microbial Drug Resistance</i> , 2021 ,	2.9	
45	Case Report: COVID-19 Recovery from Triple Infection with , HIV, and SARS-CoV-2. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020 , 103, 1597-1599	3.2	13
44	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000-17. <i>The Lancet Global Health</i> , 2020 , 8, e1162-e1185	13.6	27
43	Household stored water quality in an intermittent water supply network in Panama. <i>Journal of Water Sanitation and Hygiene for Development</i> , 2020 , 10, 298-308	1.5	2
42	Control of paratuberculosis: who, why and how. A review of 48 countries. <i>BMC Veterinary Research</i> , 2019 , 15, 198	2.7	103
41	Simplified Model to Survey Tuberculosis Transmission in Countries Without Systematic Molecular Epidemiology Programs. <i>Emerging Infectious Diseases</i> , 2019 , 25, 507-514	10.2	3
40	Overweight, Obesity, and Older Age Favor Latent Tuberculosis Infection among Household Contacts in Low Tuberculosis-Incidence Settings within Panama. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019 , 100, 1141-1144	3.2	5
39	Both B-1a and B-1b cells exposed to Mycobacterium tuberculosis lipids differentiate into IgM antibody-secreting cells. <i>Immunology</i> , 2018 , 154, 613	7.8	9
38	Mycobacterial Lipids Induce Calcium Mobilization and Degranulation of Mast Cells. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 813-816	10.2	1
37	The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. <i>Lancet Infectious Diseases, The</i> , 2018 , 18, 261-284	25.5	165
36	Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 1684-1735	40	483
35	Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 1995-2051	40	189

34	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 2091-2138	40	210
33	Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. <i>Lancet Infectious Diseases, The</i> , 2018 , 18, 1329-1349	25.5	89
32	Global variation in bacterial strains that cause tuberculosis disease: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2018 , 16, 196	11.4	43
31	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018 , 391, 2236-2271	40	381
30	Water quality effects of intermittent water supply in Arraijū, Panama. <i>Water Research</i> , 2017 , 114, 338-350.	2.5	37
29	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017 , 390, 231-266	40	352
28	Ascertaining fetal Zika virus infection based on IgM antibody test in endemic settings. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017 , 49, 809	5.8	
27	Total IgM and Anti-Phosphatidylcholine IgM Antibody Secretion Continue After Clearance of Mycobacterium bovis Bacillus Calmette-Guerin Pleural Infection. <i>Lung</i> , 2017 , 195, 517-521	2.9	1
26	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1260-1344	40	1152
25	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1211-1259	40	3432
24	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1345-1422	40	1378
23	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1423-1459	40	224
22	Global, Regional, and National Levels of Maternal Mortality, 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015. <i>Obstetrical and Gynecological Survey</i> , 2017 , 72, 11-13	2.4	18
21	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. <i>Lancet HIV,the</i> , 2016 , 3, e361-e387	7.8	382
20	Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1775-1812	40	476
19	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1603-1658	40	1216
18	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1459-1544	40	3525
17	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1545-1602	40	3801

16	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1659-1724	40	2431
15	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1725-1774	40	413
14	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1813-1850	40	302
13	<i>Mycobacterium bovis</i> in Panama, 2013. <i>Emerging Infectious Diseases</i> , 2015 , 21,	10.2	4
12	Storage in ultra-low-temperature decreases the levels of IgM anticardiolipin antibody in serum samples from tuberculosis patients. <i>Therapeutic Advances in Respiratory Disease</i> , 2014 , 8, 93-95	4.9	
11	Dyspnoea, weight loss, fever, and headache caused by extrapulmonary tuberculosis in a prison inmate. <i>Lancet, The</i> , 2014 , 384, 1400	40	
10	<i>Mycobacterium tuberculosis</i> isolates from single outpatient clinic in Panama City exhibit wide genetic diversity. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014 , 91, 310-2	3.2	3
9	Tuberculosis remains a challenge despite economic growth in Panama. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014 , 18, 286-8	2.1	3
8	Antiphospholipid IgM antibody response in acute and chronic <i>Mycobacterium tuberculosis</i> mouse infection model. <i>Clinical Respiratory Journal</i> , 2014 , 8, 137-44	1.7	6
7	Enzymatic and endpoint methods yield comparable adenosine deaminase activity in pleural fluid samples. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014 , 52, e297-300	5.9	
6	Serum samples can be substituted by plasma samples for the diagnosis of paratuberculosis. <i>Preventive Veterinary Medicine</i> , 2013 , 112, 147-9	3.1	2
5	High clustering rates of multidrug-resistant <i>Mycobacterium tuberculosis</i> genotypes in Panama. <i>BMC Infectious Diseases</i> , 2013 , 13, 442	4	7
4	Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. <i>Tuberculosis</i> , 2012 , 92, 243-7	2.6	18
3	An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis. <i>Vaccine</i> , 2012 , 30, 459-65	4.1	6
2	Mce2 operon mutant strain of <i>Mycobacterium tuberculosis</i> is attenuated in C57BL/6 mice. <i>Tuberculosis</i> , 2010 , 90, 50-6	2.6	40
1	Performance of a point of care test for detecting IgM and IgG antibodies against SARS-CoV-2 and seroprevalence in blood donors and health care workers in Panama		3